2D Skin Lesion Segmentation on ISIC 2017
85.55mIoUMambaLiteUNet
Evaluation results
| Method | Links | ||||||
|---|---|---|---|---|---|---|---|
| MambaLiteUNet2026.04 | 85.55 | 92.21 | — | 96.98 | 98.39 | 91.2 | |
| M-BFF-Net2025.10 | 85.3 | 91.15 | — | 96.34 | 97.73 | 91.77 | |
| xLSTM-VMUNetValidation Strategy=5-fold cross-validation2024.11 | 85.25 | 92 | — | — | — | — | |
| TBconvL-Net2025.10 | 84.8 | 90.89 | — | 96.07 | 97.61 | 91.19 | |
| EGE-UNet2026.04 | 83.08 | 90.76 | — | 96.55 | 98.22 | 89.4 | |
| ULVM-UNet2026.04 | 83.05 | 90.74 | — | 96.5 | 97.89 | 90.56 | |
| UNeXtValidation Strategy=5-fold cross-validation2024.11 | 82.9 | 90.8 | — | — | — | — | |
| VM-UNet2026.04 | 82.55 | 90.44 | — | 96.46 | 98.32 | 88.5 | |
| LB-UNet2026.04 | 82.4 | 90.35 | — | 96.43 | 98.46 | 87.8 | |
| VM-UNet22026.04 | 82.38 | 90.34 | — | 96.44 | 98.49 | 87.68 | |
| LightM-UNet2026.04 | 81.49 | 89.8 | — | 96.19 | 97.86 | 88.99 | |
| Med-DisSeg2026.05 | 81.4 | 89.7 | — | — | — | — | |
| UNeXt-S2026.04 | 80.91 | 89.45 | — | 96.06 | 98.06 | 87.58 | |
| CondSegVenue=AAAI 20252026.05 | 80.9 | 88.3 | — | — | — | — | |
| Swin-Unet2025.10 | 80.89 | 81.99 | — | 94.76 | 96.05 | 88.06 | |
| SkinMambaValidation Strategy=5-fold cross-validation2024.11 | 80.77 | 90 | — | — | — | — | |
| ARU-GD2025.10 | 80.77 | 87.89 | — | 93.88 | 96.31 | 88.31 | |
| C2SDG2026.04 | 80.73 | 89.34 | — | 96.01 | 97.72 | 88.65 | |
| FuseUNet2025.09 | 80.58 | 87.73 | 64.2 | — | — | — | |
| RA-Net2025.10 | 80.51 | 88.07 | — | 94.66 | 95.72 | 89.92 | |
| MALUNet2026.04 | 80.37 | 89.11 | — | 95.93 | 97.7 | 88.33 | |
| TransFuse2026.04 | 80.17 | 89 | — | 95.94 | 97.98 | 87.14 | |
| ADZUSVenue=MDPI Bioengineering 20252026.05 | 80 | 88.7 | — | — | — | — | |
| Meta-Polyp2025.10 | 79.88 | 87.69 | — | 94.96 | 96.55 | 89.53 | |
| U-Net + DSCEnhancement=DSC block2025.09 | 79.8 | 88.76 | 64.23 | — | — | — | |
| U-Net2026.04 | 79.55 | 88.61 | — | 95.72 | 97.43 | 88.36 | |
| BCDU-Net2025.10 | 79.2 | 78.11 | — | 91.63 | 97.09 | 76.46 | |
| UNet++2025.10 | 78.58 | 86.35 | — | 93.73 | 94.41 | 87.13 | |
| SCR-Net2026.04 | 78.57 | 88 | — | 95.6 | 97.93 | 85.57 | |
| ASwin U-Net2026.04 | 78.37 | 87.87 | — | 95.53 | 97.87 | 85.52 | |
| UTNetV22026.04 | 78.35 | 87.86 | — | 95.54 | 98.05 | 84.85 | |
| TransUNet2025.09 | 78.34 | 86.65 | 61.24 | — | — | — | |
| VM-UNetValidation Strategy=5-fold cross-validation2024.11 | 78.32 | 88 | — | — | — | — | |
| UNet3+2025.09 | 78.05 | 87.67 | 62.83 | — | — | — | |
| TransUNetValidation Strategy=5-fold cross-validation2024.11 | 78 | 86.8 | — | — | — | — | |
| EIU-NetVenue=Comput. Biol. Med. 20232026.05 | 77.1 | 85.5 | — | — | — | — | |
| Hiformer2025.09 | 76.95 | 85.24 | 60.31 | — | — | — | |
| FAT-Net2025.10 | 76.53 | 85 | — | 93.26 | 97.25 | 83.92 | |
| FAT-NetVenue=Med Image Anal 20222026.05 | 76.5 | 85 | — | — | — | — | |
| CE-NetVenue=TMI 20192026.05 | 76.4 | 84.8 | — | — | — | — | |
| CPFNetVenue=TMI 20202026.05 | 76.2 | 84.7 | — | — | — | — | |
| DCSAU-NetVenue=Comput. Biol. Med. 20232026.05 | 76.1 | 85 | — | — | — | — | |
| Duck-Net2025.10 | 75.94 | 84.25 | — | 93.26 | 97.25 | 83.63 | |
| U-Net2025.10 | 75.69 | 84.12 | — | 93.29 | 93.41 | 84.3 | |
| UltraLight VM-UNetValidation Strategy=5-fold cross-validation2024.11 | 75.11 | 85 | — | — | — | — | |
| U-NetVenue=MICCAI 20152026.05 | 73.7 | 82.8 | — | — | — | — | |
| VM-UNetv2Validation Strategy=5-fold cross-validation2024.11 | 73.4 | 83.3 | — | — | — | — | |
| U-Net++2025.09 | 73.34 | 84.61 | 62.65 | — | — | — | |
| U-Net2025.09 | 71.02 | 83.55 | 52.98 | — | — | — | |
| PraNetValidation Strategy=5-fold cross-validation2024.11 | 70.24 | 79.5 | — | — | — | — | |
| FANetValidation Strategy=5-fold cross-validation2024.11 | 68.51 | 78 | — | — | — | — | |
| SwinUNet2025.09 | 66.93 | 77.82 | 57.78 | — | — | — | |
| CaraNetValidation Strategy=5-fold cross-validation2024.11 | 66.03 | 75.5 | — | — | — | — | |
| Res-U-NetValidation Strategy=5-fold cross-validation2024.11 | 65.42 | 75.2 | — | — | — | — | |
| Swin-U-NetValidation Strategy=5-fold cross-validation2024.11 | 65 | 75 | — | — | — | — | |
| U-Net++Validation Strategy=5-fold cross-validation2024.11 | 63.4 | 73 | — | — | — | — | |
| Attention-U-NetValidation Strategy=5-fold cross-validation2024.11 | 62.31 | 72.1 | — | — | — | — | |
| U-Net†Validation Strategy=5-fold cross-validation2024.11 | 61.59 | 70.3 | — | — | — | — | |
| Attention R2U-NetValidation Strategy=5-fold cross-validation2024.11 | 61.28 | 70.2 | — | — | — | — | |
| R2U-NetValidation Strategy=5-fold cross-validation2024.11 | 57.6 | 67.8 | — | — | — | — |